Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek
Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.
爱文思控股（纳斯达克：VERU），一家专注于开发用于保持肌肉以实现高质量减重、肿瘤学和病毒引起的急性呼吸窘迫综合症的创新药物的临床后期生物制药公司，今天宣布了在2024年11月5日在得克萨斯州圣安东尼奥举行的肥胖周（ObesityWeek）上的一项元分析报告数据。
Highlights from the presentation:
The objective of the meta-analysis was to determine the effects of enobosarm on body composition in older patients that had obesity who were enrolled in 4 previously conducted randomized clinical trials of enobosarm that measured body composition including Phase 2 older males and postmenopausal women, Phase 2 advanced cancer patients with muscle wasting, and two Phase 3 advanced lung cancer patients with cancer wasting.
报告的亮点：
元分析的目的是判断 enobosarm 对于老年肥胖患者的体组成的影响，在4项先前进行的 enobosarm 的随机临床试验中对包括第2期老年男性和绝经后妇女、第2期患有肌肉耗损的晚期癌症患者以及两项第3期患有癌症消耗的晚期肺癌患者进行体组成测量的老年患者进行了纳入。
Meta-analysis was conducted in older (≥60 years old) subjects with obesity (BMI ≥30), treated with enobosarm 3mg per day versus placebo, and who had a Day 84 (n= 60) and Day 147 (n=45) DEXA scans to assess body composition.
在老年（≥60岁）肥胖（BMI ≥30）受试者中，比较了每天3mg enobosarm 和安慰剂的治疗效果，并具有第84天（n = 60）和第147天（n = 45）的DEXA扫描来评估体组成。
Results of DEXA scan assessments of body composition in older subjects with obesity:
At Day 84, enobosarm 3mg treatment compared to placebo resulted in an absolute increase in lean mass (0.05 kg enobosarm vs -1.54 kg placebo) and absolute decrease in fat mass (-1.48 kg enobosarm vs placebo -0.35 kg).
具有肥胖的老年受试者体组成的DEXA扫描评估结果：
在第84天，与安慰剂相比，使用enobosarm 3mg治疗导致瘦体量绝对增加（enobosarm 0.05 kg vs 安慰剂 -1.54 kg）和脂肪绝对减少（enobosarm -1.48 kg vs 安慰剂 -0.35 kg）。
At Day 147, enobosarm 3mg treatment compared to placebo resulted an absolute increase in lean mass (-0.79 kg enobosarm vs -1.77 kg placebo) and absolute decrease in fat mass (-2.05 kg enobosarm vs -0.05 kg placebo).
在第147天，与安慰剂相比，使用enobosarm 3mg治疗导致瘦体量绝对增加（enobosarm -0.79 kg vs 安慰剂 -1.77 kg）和脂肪绝对减少（enobosarm -2.05 kg vs 安慰剂 -0.05 kg）。
At Day 147, enobosarm 3mg treated subjects compared to placebo had greater total weight loss by DEXA scan (-2.93 kg for enobosarm and -2.11 kg for placebo).
在第147天，使用enobosarm 3mg治疗的受试者与安慰剂相比，通过DEXA扫描减重更多（enobosarm -2.93 kg，安慰剂 -2.11 kg）。
Enobosarm was generally well-tolerated with no increase in gastrointestinal side effects.
Enobosarm通常耐受良好，没有增加胃肠道副作用。
